MASTER-2

MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

What's the purpose of the trial?

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment.

Trial status

Accepting patients

Phase

Phase 2

Enrollment

300

Last Updated

2 weeks ago

Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Bortezomib
Daratumumab
Dexamethasone
Lenalidomide
Melphalan
Teclistamab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (MRD - Patients)

Accepting patients

Daratumumab + Lenalidomide (MRD - Patients)

Accepting patients

Teclistamab + Daratumumab (MRD + Patients)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.